Retinoblastoma Treatment (PDQ®)–Health Professional Version

SECTIONS

Changes to This Summary (05/26/2016)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

General Information About Retinoblastoma

Added text to state that the genomic landscape of retinoblastoma is driven by genomic alterations in RB1 that lead to biallelic inactivation (cited Zhang et al. as reference 9). Also added that a rare cause of RB1inactivation is chromothripsis, which may be difficult to detect by conventional methods. Added text about two studies with cases of retinoblastoma with wild-type RB1 and RB1 protein expression that showed MYCN amplification.

This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Treatment of Progressive or Recurrent Retinoblastoma

Next section >
About This PDQ Summary